CD38 and Miyoshi myopathy: This strong ectoenzyme inhibition makes isatuximab more effective in overcoming ADO‐mediated immunosuppression in the MM hypoxic tumor microenvironment, which promotes ADO generation predominantly through the CD38/CD203a/TRACP pathway.